McCaffrey T A, Pomerantz K B, Sanborn T A, Spokojny A M, Du B, Park M H, Folk J E, Lamberg A, Kivirikko K I, Falcone D J
Department of Medicine, Cornell University Medical College, New York Hospital, New York 10021.
J Clin Invest. 1995 Feb;95(2):446-55. doi: 10.1172/JCI117684.
Restenosis occurs in 35% of patients within months after balloon angioplasty, due to a fibroproliferative response to vascular injury. These studies describe a combined fibrosuppressive/antiproliferative strategy on smooth muscle cells cultured from human primary atherosclerotic and restenotic coronary arteries and from normal rat aortas. L-Mimosine suppressed the posttranslational hydroxylation of the precursors for collagen and for eukaryotic initiation factor-5A (eIF-5A) by directly inhibiting the specific protein hydroxylases involved, prolyl 4-hydroxylase (E.C. 1.14.11.2) and deoxyhypusyl hydroxylase (E.C. 1.14.99.29), respectively. Inhibition of deoxyhypusyl hydroxylation correlated with a dose-dependent inhibition of DNA synthesis. Inhibition of prolyl hydroxylation caused a dose-dependent reduction in the secretion of hydroxyproline-containing protein and decreased the formation of procollagen types I and III. The antifibroproliferative action could not be attributed to nonspecific or toxic effects of mimosine, appeared to be selective for the hydroxylation step in the biosynthesis of the procollagens and of eIF-5A, and was reversible upon removal of the compound. The strategy of targeting these two protein hydroxylases has important implications for the pathophysiology of restenosis and for the development of agents to control fibroproliferative diseases.
35%的患者在球囊血管成形术后数月内会发生再狭窄,这是对血管损伤的一种纤维增生性反应所致。这些研究描述了一种针对从人类原发性动脉粥样硬化和再狭窄冠状动脉以及正常大鼠主动脉培养的平滑肌细胞的联合纤维抑制/抗增殖策略。L-含羞草碱通过直接抑制所涉及的特定蛋白质羟化酶,即脯氨酰4-羟化酶(E.C. 1.14.11.2)和脱氧hypusyl羟化酶(E.C. 1.14.99.29),分别抑制胶原蛋白和真核起始因子-5A(eIF-5A)前体的翻译后羟化。脱氧hypusyl羟化的抑制与DNA合成的剂量依赖性抑制相关。脯氨酰羟化的抑制导致含羟脯氨酸蛋白分泌的剂量依赖性减少,并降低了I型和III型前胶原的形成。这种抗纤维增生作用不能归因于含羞草碱的非特异性或毒性作用,似乎对前胶原和eIF-5A生物合成中的羟化步骤具有选择性,并且在去除该化合物后是可逆的。靶向这两种蛋白质羟化酶的策略对再狭窄的病理生理学以及控制纤维增生性疾病药物的开发具有重要意义。